# A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

> **NCT02395133** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 422 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02395133
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-25
- **Primary completion:** 2016-07
- **Final completion:** 2016-10-18
- **Target enrollment:** 422 (ACTUAL)
- **Last updated:** 2020-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02395133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02395133, "A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02395133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*